Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

181. Bisphosphonates for Osteoporosis - Where Do We Go from Here? (PubMed)

Bisphosphonates for Osteoporosis - Where Do We Go from Here? 22571168 2012 06 05 2013 01 11 1533-4406 366 22 2012 May 31 The New England journal of medicine N. Engl. J. Med. Bisphosphonates for osteoporosis--where do we go from here? 2048-51 10.1056/NEJMp1202619 Whitaker Marcea M Division of Reproductive and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA. Guo Jia J Kehoe Theresa T Benson George G eng Journal Article 2012 05 09 United (...) States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM Bone Density drug effects Bone Density Conservation Agents pharmacology therapeutic use Diphosphonates pharmacology therapeutic use Fractures, Bone epidemiology prevention & control Humans Osteoporosis drug therapy Risk Spinal Fractures epidemiology prevention & control 2012 5 11 6 0 2012 5 11 6 0 2012 6 6 6 0 ppublish 22571168 10.1056/NEJMp1202619

2012 NEJM

182. Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? (PubMed)

Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? 22571169 2012 06 05 2018 11 13 1533-4406 366 22 2012 May 31 The New England journal of medicine N. Engl. J. Med. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? 2051-3 10.1056/NEJMp1202623 Black Dennis M DM Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. Bauer Douglas C DC Schwartz Ann V AV Cummings Steven R SR Rosen Clifford J CJ eng K24 (...) AR051895 AR NIAMS NIH HHS United States Journal Article 2012 05 09 United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM Bone Density drug effects Bone Density Conservation Agents administration & dosage pharmacology Diphosphonates administration & dosage pharmacology Drug Administration Schedule Fractures, Bone epidemiology prevention & control Humans Osteoporosis drug therapy Risk Spinal Fractures epidemiology prevention & control 2012 5 11 6 0 2012 5

Full Text available with Trip Pro

2012 NEJM

183. Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly

Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly UTCAT2269, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly Clinical Question In a patient currently taking oral bisphosphonates, what is the likelihood of bisphosphonates induced osteonecrosis after dental extractions (...) ? Clinical Bottom Line In patients taking oral bisphosphonates, the risk of bisphosphonate induced osteonecrosis after dental extraction is slightly increased. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Pazianas/2007 11 publications reporting 26 cases of ONJ in patients receiving bisphosphonates for the treatment of osteoporosis Systematic Review of: case reports, case series and observational studies

2012 UTHSCSA Dental School CAT Library

184. Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established

Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established UTCAT2217, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established Clinical Question Do patients with osteoporosis have a higher incidence of periodontal disease than the general population? Clinical Bottom Line The relationship between osteoporosis (...) and periodontal disease cannot be established based on available data. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Martinez-Maestre/2010 35 selected trials Systematic review of clinical trials Key results Few studies have been performed to demonstrate an association between systemic osteoporosis and fractures to dental loss. Most, from the few done, have found a positive correlation (five out of seven

2012 UTHSCSA Dental School CAT Library

185. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model

The economics of improving medication adherence in osteoporosis: validation and application of a simulation model The economics of improving medication adherence in osteoporosis: validation and application of a simulation model The economics of improving medication adherence in osteoporosis: validation and application of a simulation model Patrick AR, Schousboe JT, Losina E, Solomon DH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of a hypothetical behavioural intervention to improve adherence to osteoporosis medication in women starting bisphosphonate therapy. The authors concluded that behavioural interventions were likely to be cost-effective in most scenarios, especially

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

186. Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms

Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions Rapid Response Report: Systematic Review Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms February 2012 CADTH Cite as: Gauthier K, Bai A, Perras C (...) , Cunningham J, Ahuja,T, Richter, T, Kovacs, C. Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2012 (Rapid Response Report: Systematic Review). Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

187. Denosumab(Prolia) for osteoporosis. New mechanism but questionable efficacy

Denosumab(Prolia) for osteoporosis. New mechanism but questionable efficacy 02/2012 Denosumab( Prolia ® ) for osteoporosis New mechanism but questionable efficacy Indications 1 Treatment of osteoporosis in postmenopausal women at increased risk of fractures. Treat- ment of bone loss associated with hormone ablation in men with prostate cancer at in- creased risk of fractures. Mechanism of action and pharmacokinetics 1 This monoclonal antibody impedes the inter- action between RANKL/RANK (...) supplements should be added to the diet if daily uptake and sun ex- posure are not sufficient. Clínical efficacy Osteoporosis in postmenopause women The FREEDOM 3 study compared denosumab 60 mg every 6 months for 3 years in 7,807 postmenopausal women with or without any previous fracture, between 60 and 90 years and with basal lumbar or hip T-scores be- tween -2.5 and -4.0. The estimated absolute average probability of fracture after 10 years was 18.6% for major osteoporotic fractures and 7.33% for hip

2012 Drug and Therapeutics Bulletin of Navarre (Spain)

188. Bone-density testing interval and transition to osteoporosis in older women. (PubMed)

Bone-density testing interval and transition to osteoporosis in older women. Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, -2.50 or lower) is recommended for women 65 years of age or older, there are few data to guide decisions about the interval between BMD tests.We studied 4957 women, 67 years of age or older, with normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.01 to -2.49) and with no history of hip (...) or clinical vertebral fracture or of treatment for osteoporosis, followed prospectively for up to 15 years. The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors. Transitions from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed with the use of parametric cumulative incidence models

Full Text available with Trip Pro

2012 NEJM

189. Osteoporosis

Osteoporosis Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2012 American College of Obstetricians and Gynecologists

190. Osteoporosis in Men

Osteoporosis in Men We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation (...) Article navigation 1 June 2012 Article Contents Article Navigation Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline Nelson B. Watts 1Mercy Health Osteoporosis & Bone Health Services (N.B.W.), Cincinnati Ohio 45236 Search for other works by this author on: Robert A. Adler 2McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine (R.A.A.), Richmond, Virginia 23298 Search for other works by this author on: John P. Bilezikian 3Columbia University

Full Text available with Trip Pro

2012 The Endocrine Society

191. Osteoporosis: assessing the risk of fragility fracture

Osteoporosis: assessing the risk of fragility fracture Osteoporosis: assessing the risk of Osteoporosis: assessing the risk of fr fragility fr agility fracture acture Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg146 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osteoporosis: assessing the risk of fragility fracture (CG146) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

192. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies

How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies Ferko NC, Borisova N, Airia P, Grima DT, Thompson MF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to explore the effect of varying rebates, co-payments and delivery of drugs (oral or intravenous) on the cost-effectiveness of osteoporosis treatment, for managed care organisations. The authors concluded that the cost-effectiveness of the drugs varied considerably when these factors were

2012 NHS Economic Evaluation Database.

193. Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

2012 Evidence-Based Medicine (Requires free registration)

194. Vitamin D supplementation in patients with osteoporosis

Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vitamin D supplementation in patients with osteoporosis. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions The purpose (...) of vitamin D supplementation is to improve bone and muscle health, thereby reducing the risk of osteoporosis-related fractures. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Bone Densitys; Dietary Supplements; Osteoporosis; Vitamin D; Vitamins Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200

2012 Health Technology Assessment (HTA) Database.

195. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of secondary plus tertiary prevention of osteoporosis by identifying post-menopausal women who were at increased risk of fractures, compared with tertiary prevention alone. The authors concluded that both prevention strategies were cost-effective compared with no prevention. Secondary plus tertiary prevention was more effective and more

2012 NHS Economic Evaluation Database.

196. Fracture risk and zoledronic acid therapy in men with osteoporosis. (PubMed)

Fracture risk and zoledronic acid therapy in men with osteoporosis. Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion (...) <0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%).Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

Full Text available with Trip Pro

2012 NEJM

197. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

198. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

199. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

200. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. (PubMed)

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. The best strategies to screen postmenopausal women for osteoporosis are not clear.To identify the cost-effectiveness of various screening strategies.Individual-level state-transition cost-effectiveness model.Published literature.U.S. women aged 55 years or older.Lifetime.Payer.Screening strategies composed of alternative tests (central dual-energy x-ray absorptiometry [DXA], calcaneal quantitative (...) ultrasonography [QUS], and the Simple Calculated Osteoporosis Risk Estimation [SCORE] tool) initiation ages, treatment thresholds, and rescreening intervals. Oral bisphosphonate treatment was assumed, with a base-case adherence rate of 50% and a 5-year on/off treatment pattern.Incremental cost-effectiveness ratios (2010 U.S. dollars per quality-adjusted life-year [QALY] gained).At all evaluated ages, screening was superior to not screening. In general, quality-adjusted life-days gained with screening tended

Full Text available with Trip Pro

2011 Annals of Internal Medicine